MASTERINVEST Kapitalanlage GmbH Makes New $966,000 Investment in Becton, Dickinson and Company $BDX

MASTERINVEST Kapitalanlage GmbH bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, Holdings Channel reports. The firm bought 5,607 shares of the medical instruments supplier’s stock, valued at approximately $966,000.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Becton, Dickinson and Company by 53.9% in the 1st quarter. Raymond James Financial Inc. now owns 1,230,068 shares of the medical instruments supplier’s stock valued at $281,759,000 after buying an additional 431,026 shares in the last quarter. Steward Partners Investment Advisory LLC grew its stake in shares of Becton, Dickinson and Company by 4.8% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 29,485 shares of the medical instruments supplier’s stock valued at $6,754,000 after buying an additional 1,343 shares in the last quarter. Northwest & Ethical Investments L.P. raised its position in Becton, Dickinson and Company by 42.0% during the first quarter. Northwest & Ethical Investments L.P. now owns 33,679 shares of the medical instruments supplier’s stock valued at $7,715,000 after acquiring an additional 9,960 shares in the last quarter. Finally, HFR Wealth Management LLC lifted its stake in Becton, Dickinson and Company by 2.0% in the first quarter. HFR Wealth Management LLC now owns 33,276 shares of the medical instruments supplier’s stock valued at $7,622,000 after acquiring an additional 652 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 0.2%

BDX stock opened at $200.82 on Monday. The stock has a market capitalization of $57.32 billion, a price-to-earnings ratio of 34.45, a price-to-earnings-growth ratio of 1.86 and a beta of 0.25. The company has a 50-day moving average of $188.90 and a two-hundred day moving average of $184.66. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.32 billion for the quarter. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a $1.05 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Royal Bank Of Canada dropped their price target on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a research note on Friday, November 7th. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus cut their target price on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Piper Sandler decreased their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Finally, Jefferies Financial Group increased their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus price target of $204.91.

Insider Activity

In related news, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 407 shares of company stock valued at $73,922 in the last 90 days. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.